2014
DOI: 10.1007/s11156-014-0471-3
|View full text |Cite
|
Sign up to set email alerts
|

Innovation capability and post-IPO performance

Abstract: This paper studies how firms' innovation capability is related to their stock performance and eventual survival for a sample of biotech IPO firms. We create productrelated measures of firms' innovation capability by tracking the changes in R&D expenses, products, patents, strategic alliances, and product development stages for our sample firms, as disclosed in their IPO prospectuses and third post-IPO 10-K filings. We find that innovation capability is critical to contemporaneous stock performance and eventual… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
14
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(14 citation statements)
references
References 63 publications
0
14
0
Order By: Relevance
“…The latter paper finds that the stage of product development, availability of patent protection, and venture capital backing are important determinants of disclosure, and that such disclosures lead to valuation benefits such as reduced bid-ask spreads and return volatility. Other research examines the value of financial and nonfinancial performance metrics in the biotechnology industry (Ely, Simko, and Thomas 2003;Guedj and Scharfstein 2004;Guedj 2005;Hand 2005;Xu, Magnan, and André 2007;Callen, Gavious, and Segal 2010;Guo and Zhou 2014). We complement this research by providing evidence that biotechnology firms increase product-level disclosures as the intensity of news (good or bad) increases.…”
Section: Introductionmentioning
confidence: 94%
“…The latter paper finds that the stage of product development, availability of patent protection, and venture capital backing are important determinants of disclosure, and that such disclosures lead to valuation benefits such as reduced bid-ask spreads and return volatility. Other research examines the value of financial and nonfinancial performance metrics in the biotechnology industry (Ely, Simko, and Thomas 2003;Guedj and Scharfstein 2004;Guedj 2005;Hand 2005;Xu, Magnan, and André 2007;Callen, Gavious, and Segal 2010;Guo and Zhou 2014). We complement this research by providing evidence that biotechnology firms increase product-level disclosures as the intensity of news (good or bad) increases.…”
Section: Introductionmentioning
confidence: 94%
“…First, successful corporate innovation enhances a firm's future and boosts its stock price in the long-term. For instance, innovation, in terms of research and development investments, plays a critical role in the success of a firm's initial public offerings (Guo and Zhou [28]) and operating and stock price performance (Chan et al [29]; Eberhart et al [30]) over the long term. Thus, it may be in the best interests of controlling shareholders to increase innovation to boost the stock price in the long term.…”
Section: Background Literature Review and Hypothesis Developmentmentioning
confidence: 99%
“…For the measurement of overarching innovation capability construct, “commonly used measures such as the total R&D expenditure and patents” (Guo and Zhou, 2016, p. 2) are deployed. Consequently, it follows that for PIC measurement, reflective indicators pertaining to product innovation outcomes and/or resource investments are typically used in empirical research (Grawe et al , 2009; O’Cass and Ngo, 2012).…”
Section: Conventional Pic Measures and The Challenge Of Capturing Multidimensionality Of Dynamic Capabilitiesmentioning
confidence: 99%